HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease (NCT02855476)
🩺 Plain-English Summary (8th-Grade Level)
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Who can join: Review the eligibility criteria below.
Location: Cenexel — Englewood, Colorado
Age range: 11 Years to 75 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- Cenexel — Englewood, Colorado
- Georgetown University — Washington D.C., District of Columbia
- John Hopkins University — Baltimore, Maryland
- Wake Forest University — Winston-Salem, North Carolina
- Vanderbilt University Medical Center — Nashville, Tennessee
- University of Texas Health Science Center — Houston, Texas
- University of British Columbia, The Centre for Huntingtons Disease — Vancouver, British Columbia
- The Ottawa Hospital — Ottawa, Ontario
- North York General Hospital — Toronto, Ontario
- Centre for Movement Disorders — Toronto, Ontario
- Centre Hospitalier Universitaire d'Angers — Angers,
- Le Centre Hospitalier Universitaire de Bordeaux — Bordeaux,
- University Hospital Ulm — Ulm, Baden-Wurttemberg
- Dresden University — Dresden, Saxony
- St Josef And Elisabeth Hospital — Bochum,
- University Hospital of Erlangen — Erlangen,
- George Huntington Institute — Münster,
- Kbo-Isar-Amper-Klinikum Taufkirchen (Vils) — Taufkirchen,
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta — Milan,
- Lega Italiana Ricera Huntington — Rome,
- The University of Auckland — Grafton, Auckland
- NZ Brain Research Institute — Christchurch, Canterbury
- Institute of Psychiatry and Neurology — Warsaw,
- Gulbenkian Institute of Molecular Medicine — Lisbon,
- Cruces University Hospital — Bilbao, Biscay
📞 Contact the Study Coordinator
Phone: (303) 867-5473
Email: j.crall@cenexel.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Huntington's Disease
- Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease — Birmingham, Alabama
- A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease — Edmonton,
- Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort — Birmingham, Alabama
Explore by condition: All Huntington's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.